Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Cancer Lett. 2015 Sep 1;369(1):229–241. doi: 10.1016/j.canlet.2015.08.021

Table 1.

OXi8006 and OXi8007 inhibited the growth of activated human umbilical vein endothelial cells (HUVECs) and human breast cancer cells (MDA-MB-231).

Doxorubicin
(nM)
OXi8006 (nM) OXi8007 (nM)
HUVECs (activated) 48.7±45.9 33.4±1.13 40.6±9.9
MDA-MB-231 116±101 37.5±8.5 31.9±11.6

Values were derived from SRB assay of a minimum of at least 3 independent experiments and are presented as averaged GI50 values ± S.D.